Evaluate Vantage Homepage
Esmo 2021 – Enhertu sets a very high bar
A move into the larger second-line breast cancer setting is surely on the way for the Astrazeneca and Daiichi drug.
Esmo 2021 – colorectal cancer could be Mirati’s golden ticket
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
Esmo 2021 – Opdivo’s glimmer of hope in front-line head and neck cancer
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Medtech
Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
Company Events
Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
Nektar again looks to bempeg to sweeten its valuation
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
Mirati fiddles as its share price burns
Speedy US approval for Amgen’s Lumakras was an embarrassment for Mirati, which has gone quiet as its share price has drifted downwards.
Interviews
Amylyx changes its mind about an early filing
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
Astellas readies roxadustat for launch
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
